APGE

APGE

USD

Apogee Therapeutics Inc. Common Stock

$54.710-0.290 (-0.527%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$55.000

الأعلى

$55.930

الأدنى

$52.340

الحجم

1.04M

أساسيات الشركة

القيمة السوقية

3.7B

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

0.66M

البورصة

NGM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $26.2الحالي $54.710الأعلى $63.5

أخبار ذات صلة

GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026,

عرض المزيد
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Craig-Hallum Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $109

Craig-Hallum analyst Adam Vogel initiates coverage on Apogee Therapeutics with a Buy rating and announces Price Target of $109.

عرض المزيد
Craig-Hallum Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $109
Analyst Upgrades

RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics with a Outperform and raises the price target from $60 to $70.

عرض المزيد
RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70
GlobeNewswire

Apogee Therapeutics to Participate in Upcoming Conferences

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2nd

عرض المزيد
Apogee Therapeutics to Participate in Upcoming Conferences
Analyst Upgrades

Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105

Mizuho analyst Joseph Catanzaro initiates coverage on Apogee Therapeutics with a Outperform rating and announces Price Target of $105.

عرض المزيد
Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.